Glaxosmithkline Share News (GSK)

GlaxoSmithKline's ViiV To Collaborate With Janssen On HIV-1 Treatment

BROKER RATINGS SUMMARY: S&P CapIQ Cuts Next To Buy From Strong Buy

Independent group says new Glaxo asthma drug far too expensive

Dec 21 (Reuters) - An independent nonprofit organization that evaluates clinical and cost effectiveness of new medicines found the price of GlaxoSmithKline's new drug for severe asthma should be as much as 76 percent lower to justify its value, according to the group's latest draft report.

Microsaic Systems Appoints Bevan Metcalf As Finance Director

Glaxo Deal To Sell Ofatumumab Auto-Immune Indication Rights Completes

UPDATE 1-GSK to buy HIV drugs from Bristol-Myers Squibb for initial $350 mln

(Adds details, background) LONDON, Dec 18 (Reuters) - Pharmaceutical group GlaxoSmithKline said its majority-owned HIV business would buy drugs at different stages of development from U.S. rival Bristol-Myers Squibb for an initial $350 million. GSK said the acquisitions would provide

GlaxoSmithKline acquires HIV assets

(ShareCast News) - GlaxoSmithKline's HIV business has reached a couple of deals with Bristol-Myers Squibb to acquire its late-stage HIV research and development assets as well as its portfolio of preclinical and discovery stage HIV research assets. Under the agreements, ViiV Healthcare will acquire

GSK to buy HIV drugs from Bristol-Myers Squibb

LONDON, Dec 18 (Reuters) - British pharmaceutical company GlaxoSmithKline said it would buy HIV drugs at different stages of development from U.S. rival Bristol-Myers Squibb in a deal which would boost its ViiV Healthcare unit. GSK said it would pay an initial $317 million to buy the late

GlaxoSmithKline's ViiV Venture To Buy Bristol-Myers HIV Assets

GlaxoSmithKline gets positive trial results for rheumatoid arthritis treatment

(ShareCast News) - Pharmaceuticals giant GlaxoSmithKline announced positive top-line results from the phase III programme investigating sirukumab, which is used for the treatment of patients with moderately to severely active rheumatoid arthritis. Sirukumab, which is being developed as part of a col

GlaxoSmithKline Gets Positive Phase III Trial Results For Sirukumab

UPDATE 3-Sanofi plans to reshape via $20 bln asset swap with Boehringer

* Sanofi in talks to acquire Boehringer consumer health * Boehringer to buy Sanofi's animal health arm Merial * Planned deal shows drive by new CEO to simplify Sanofi * Sanofi shares jump more than 4 percent (Adds banks advising Boehringer, Boehringer comment on financing, upd

Amgen reacquires rights to three drugs from Glaxo in 48 countries

Dec 14 (Reuters) - Amgen Inc on Monday said it had reached a deal with British drugmaker GlaxoSmithKline to reacquire the sales rights to three of its products in 48 countries, including Australia as well as markets in Asia, South America and Europe. The three Amgen drugs are the osteoporos

BUZZ-GlaxoSmithKline: new lung drugs starting to gain momentum

** GlaxoSmithKline's new inhaled lung drugs finally building momentum in all-important U.S. market, with Breo weekly prescriptions hitting 30,000 and Anoro/Incruse also improving, according to IMS data ** GSK insiders say more focused approach by U.S. sales force helping, after earlier disa

UPDATE 1-U.S. FDA advisers recommend approval of Teva asthma drug for adults

(Adds background) Dec 9 (Reuters) - An advisory committee to the U.S. Food and Drug Administration recommended on Wednesday that the agency approve Teva Pharmaceutical Industries Ltd's Read more